Dirk M Zahm

发表

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.